Delving into the Latest Updates on DXP-106 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

DXP 106, DXP106

Target

IL1RAP

Action

inhibitors

Mechanism

IL1RAP inhibitors(Interleukin-1 receptor accessory protein inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid NeoplasmNeoplasms

Inactive Indication-

Originator Organization

Beijing Danxu Biopharmaceutical Co., Ltd.

Active Organization

Beijing Danxu Biopharmaceutical Co., Ltd.Zhuhai Danxu Biopharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Part 1单药剂量递增阶段主要目的：评价DXP-106在晚期实体瘤患者中的安全性和耐受性；探索DXP-106在晚期实体瘤患者中的剂量限制性毒性（DLT），并确定最大耐受剂量（MTD）和/或Ⅱ期推荐剂量（RP2D）。 Part 2联合用药剂量递增阶段主要目的：评价DXP-106在晚期实体瘤患者中联合标准化疗给药后的安全性和耐受性；探索DXP-106与标准化疗联用的推荐剂量和/或优势瘤种。

[Translation]

Part 1: Monotherapy Dosage Escalation Phase Main Objectives: To evaluate the safety and tolerability of DXP-106 in patients with advanced solid tumors; To explore dose-limiting toxicities (DLTs) of DXP-106 in patients with advanced solid tumors and determine the maximum tolerated dose (MTD) and/or the recommended dose for Phase II (RP2D). Part 2: Combination Therapy Dosage Escalation Phase Main Objectives: To evaluate the safety and tolerability of DXP-106 in combination with standard chemotherapy in patients with advanced solid tumors; To explore the recommended dose and/or preferred tumor types for combination therapy of DXP-106 with standard chemotherapy.

Start Date-

Sponsor / Collaborator

Zhuhai Danxu Biopharmaceutical Co., Ltd.

100 Clinical Results associated with DXP-106

Login to view more data

100 Translational Medicine associated with DXP-106

Login to view more data

100 Patents (Medical) associated with DXP-106

Login to view more data

100 Deals associated with DXP-106

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	Zhuhai Danxu Biopharmaceutical Co., Ltd.	12 Mar 2026
Neoplasms	Preclinical	China	Beijing Danxu Biopharmaceutical Co., Ltd.	01 Apr 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data